Angela Labrozzi, channel partner director, Within3, outlines how an asynchronous clinical trials model can help pharma and healthcare companies lower emissions, save money, and maximise time.
Simon Tilley, SAS, breaks down the benefits and drawbacks of decentralised clinical trials (DCT). He also explains how AI, machine learning and advanced analytics can refine all stages from participant recruitment to compiling results.
EPM conducted a roundtable with several pharma experts to learn what pharma industry trends to watch out for in 2023, from AI drug discovery through to the rise of decentralised trials.
Co-founded by the cancer institute Gustave Roussy, Paris-Saclay University and the French company Clevexel Pharma, Graegis Pharmaceuticals plans to start proof-of-concept clinical trials in 2023 in the prevention of radiation-induced dermatitis.
EPM held a Q&A session with Vincent Rolland, Idorsia Pharmaceuticals, and Richard Young, Veeva, to discuss how investing in digital data management can benefit biopharma, from clinical trials through to market.
Melissa Mooney, director of eCOA Solutions Engineering at IQVIA, explains how successful oncology drug development relies on an accurate depiction of the patient voice, as well as 5 key considerations for developing a patient-centric eCOA strategy.
Sally-Anne Whybrow, healthcare business development manager, Siemens Financial Services, UK examines how smart financing can help CROs invest in financially-sustainable technology.
Dr. Karen Rowland Yeo, senior vice president, Client & Regulatory Strategy, Certara UK, describes how pioneering biosimulation is helping to predict drug exposures during pregnancy, providing opportunities for safer care and better outcomes.
Jason Smith, CTO, AI & Analytics, Within3, describes the possibilities made by AI in supporting the life sciences sector, and how it can allow pharma experts to produce real time results and yield better insights.
Richard Young, vice president of Vault CDMS - Veeva Systems gives EPM some insight how a centralised data strategy can effectively manage clinical data.
Paul O’Donohoe - senior director of eCOA Product and Science at Medidata, a Dassault Systèmes company, explains how decentralised clinical trials came to be during the Covid-19 pandemic.
Sharon Lamb, partner, and David Gibson, senior associate, McDermott Will & Emery analyse the MHRA consultation to change the UK clinical trial regulations.
